Objective To explore the comparative clinical efficacy and safety outcomes of
anticoagulation before (pre-) or following (post-) thrombolytic therapy in systemic …

Abstract Background Randomized controlled trials (RCTs) comparing systemic thrombolysis
to anticoagulation in intermediate risk pulmonary embolism (PE) have yielded mixed results …

Background The use of thrombolytic therapy in patients with intermediate-risk pulmonary
embolism is controversial. To compare with anticoagulation alone, no analysis before has …

Background: Pulmonary emboli (PE) represents an extended spectrum of diseases. 10% of
submassive PE progress to massive PE, and while overall mortality is around 5%, it can …

Why do we not have a precise answer to the question of which patients with pulmonary
embolism (PE), particularly intermediate risk (submassive) PE, ought to receive fibrinolysis …

There are limited and conflicting data on the initial management of intermediate-risk (or
submassive) pulmonary embolism (PE). This study sought to compare the outcomes of …

Background The use of thrombolysis in patients with acute, intermediate-risk pulmonary
embolism (PE) remains controversial. This meta-analysis compared the efficacy and safety …

Background: Therapeutic options for intermediate-or high-risk pulmonary embolism (PE)
include anticoagulation, systemic thrombolysis and catheter-directed thrombolysis (CDT); …

Anticoagulation (AC) is a sine qua non for the treatment of venous thromboembolism. The
addition of thrombolytics to AC is associated with more effective and efficient lysis of the …

Background Benefit of thrombolytic therapy in patients with massive pulmonary embolism
(PE) is evident. However, evidence supporting benefit in clinical outcomes of this approach …